Skip to content

Biohaven BHVN Accrued Manufacturing Costs

Accrued Manufacturing Costs at other companies

Eli Lilly logo
Eli LillyLLY
Roivant Sciences logo
Roivant SciencesROIV
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's accrued manufacturing costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's accrued manufacturing costs?
Biohaven (BHVN) reported accrued manufacturing costs of $4.43M in Q1 2026.
How has Biohaven's accrued manufacturing costs changed year-over-year?
Biohaven's accrued manufacturing costs decreased by 32.1% year-over-year, from $6.53M to $4.43M.
What is the long-term trend for Biohaven's accrued manufacturing costs?
Over 4 years (2021 to 2025), Biohaven's accrued manufacturing costs has grown at a 15.2% compound annual growth rate (CAGR), from $9.54M to $16.78M.